Oral News and Research

RSS

New registry data shows semaglutide does not cause pancreatic cancer

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway.

29 Sep 2026

From espresso to filter coffee, brewing may shape what reaches your gut

A focused narrative review traces how caffeine, chlorogenic acids, and coffee fibers move through the gut and interact with microbes. The authors identify plausible links between the microbiome and liver health, but human studies have not shown that microbiome changes cause coffee’s reported metabolic benefits.

28 Sep 2026

Study identifies inconsistent care routines for internal head and neck lymphedema

Internal head and neck lymphedema develops when cancer treatment damages or obstructs lymphatic drainage, causing fluid to accumulate in the oral cavity, pharynx, or larynx.

28 Sep 2026

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and at different life stages – premenopausal, experiencing menopause, or post-menopausal.

28 Sep 2026

Exam stress significantly raises blood sugar levels in medical students

Exam stress is associated with significant increases in blood sugar levels in medical students both during exams and the days leading up to them, according to new research being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

27 Sep 2026

Gut bacteria signature may predict type 2 diabetes risk

Changes in the composition of bacteria in the gut could provide early warning of type 2 diabetes (T2D), new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found.

27 Sep 2026

Ultra-low-dose radiation therapy eases painful bone lesions in multiple myeloma

A short course of ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients in a multi-institutional phase 2 clinical trial.

27 Sep 2026

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorization under exceptional circumstances for NEZGLYAL® (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd)-negative brain lesions.

26 Sep 2026

MD Anderson researchers showcase new findings in radiation oncology at ASTRO 2026

Experts from The University of Texas MD Anderson Cancer Center will present nearly 70 abstracts at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.

25 Sep 2026

New pre-hospital blood test reduces unnecessary emergency department visits for chest pain

Researchers in The Netherlands have found that about 30% of presentations to emergency departments of patients with chest pain could be avoided if a highly sensitive troponin test is used in combination with other parameters by ambulance crews during pre-hospital triaging.

25 Sep 2026

Multi-million dollar grants aim to advance hairy cell leukemia research

The Hairy Cell Leukemia Foundation and Blood Cancer United®, formerly The Leukemia & Lymphoma Society, today announced six new research grants as part of their ongoing strategic partnership to better understand what drives hairy cell leukemia and find better therapies on the road to cures for this rare form of blood cancer.

24 Sep 2026

Study finds oral hormone replacement therapy increases venous thromboembolism risk

Current use of oral menopausal hormone therapy (commonly known as hormone replacement therapy or HRT) is associated with an increased risk of blood clots in legs / lungs regardless of dose or treatment duration, finds a large Danish study published by The BMJ today.

23 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026

A chemical used in BPA-free products may have a connection to diabetes control

In adults with type 2 diabetes receiving oral glucose-lowering therapy, higher plasma BPS concentrations were associated with higher HbA1c after accounting for demographic factors, medication adherence, and diet, whereas BPA was not associated with HbA1c. The BPS association was modest and no longer statistically significant after further adjustment for BPA, BMI, and physical fitness, supporting the need for larger studies to determine whether reducing exposure could improve glycemic control.

23 Sep 2026

NIH funds national center to advance root canal alternatives

Which would you rather have: a root canal or a pulpotomy? Even if you're not familiar with a pulpotomy, you might be inclined to learn more.

23 Sep 2026

C-Path awards $1.7 million to advance five drug development projects

Critical Path Institute (C-Path) today announced that its Translational Therapeutics Accelerator has awarded $1,699,500 through five Bridging Research and Innovation in Drug Development Grants (BRIDGe).

22 Sep 2026

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced the establishment of a dedicated Alzheimer's Disease Scientific Advisory Board (SAB).

From Galimedix Therapeutics, INC. 22 Sep 2026

Prenatal cannabis exposure linked to subtle brain and behavioral differences in children

A large ABCD study of 10,838 children found that prenatal cannabis exposure was associated with small differences in resting-state brain connectivity, higher behavioral and emotional problem scores, and lower performance on several cognitive measures in late childhood. PCE-related connectivity patterns partly overlapped with those linked to psychopathology and cognition, although the cross-sectional observational design cannot establish causality or mediation.

22 Sep 2026

Updated clinical guideline offers strategies to reduce vaccination distress

A comprehensive guideline update with 16 recommendations to reduce vaccination distress, with suggestions ranging from applying topical pain relief to distractions, has been published in the Canadian Medical Association Journal.

21 Sep 2026

EVITA clinical trial evaluates oral vitamin C for pre-cancerous blood disorders

Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off.

21 Sep 2026

Oral News and Research

New registry data shows semaglutide does not cause pancreatic cancer

From espresso to filter coffee, brewing may shape what reaches your gut

Study identifies inconsistent care routines for internal head and neck lymphedema

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

Exam stress significantly raises blood sugar levels in medical students

Gut bacteria signature may predict type 2 diabetes risk

Ultra-low-dose radiation therapy eases painful bone lesions in multiple myeloma

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

MD Anderson researchers showcase new findings in radiation oncology at ASTRO 2026

New pre-hospital blood test reduces unnecessary emergency department visits for chest pain

Multi-million dollar grants aim to advance hairy cell leukemia research

Study finds oral hormone replacement therapy increases venous thromboembolism risk

Semaglutide’s heart benefits may extend beyond weight loss

A chemical used in BPA-free products may have a connection to diabetes control

NIH funds national center to advance root canal alternatives

C-Path awards $1.7 million to advance five drug development projects

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

Prenatal cannabis exposure linked to subtle brain and behavioral differences in children

Updated clinical guideline offers strategies to reduce vaccination distress

EVITA clinical trial evaluates oral vitamin C for pre-cancerous blood disorders

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News